INTRODUCTION {#S1}
============

During mouse development, the Ets factor *Erg* is sequentially expressed in endothelial cells (ECs) of the yolk sac blood islands \[embryonic day (E) 7.5\], ECs of the developing vasculature (E8.5), and then in chondrocytes of the developing cartilage (E10.5) ([@R57]). Overexpression of Erg in zebrafish promotes the proliferation of mesodermal angioblasts ([@R18]). Knockdown of *Erg* in murine embryonic stem (ES) cells significantly reduces their differentiation into ECs ([@R40]). Whereas *Erg* expression gradually decreases in the developing vasculature of zebrafish, *Erg* remains highly expressed in ECs of most adult tissues in mouse and human ([@R3]; [@R57]; [@R24]; [@R18]; [@R64]). Erg can function as a transcriptional activator of several EC-restricted genes, including angiopoietin 2, endoglin, *Vwf* and VE-cadherin (*VE-cad*; cadherin 5) ([@R6]; [@R65]; [@R50]; [@R42]; [@R23]). Erg also acts as a transcriptional repressor of pro-inflammatory genes in ECs; for example, Erg represses the chemokine interleukin 8 to promote endothelial quiescence and inhibit neutrophil attachment in response to pro-inflammatory cytokines such as tumor necrosis factor ([@R64]).

During mouse and chicken bone development, *Erg* is selectively expressed in articular chondrocytes ([@R26]; [@R27]; [@R28]). *Erg* is induced by the bone morphogenetic protein Gdf5 and is highly expressed in regions of the articular cartilage that express lubricin (Prg4) ([@R26]). Interestingly, overexpression of Erg in developing chick limbs effectively blocks maturation of endochondral ossification by maintaining the entire limb chondrocyte population in an immature state ([@R26]).

*Erg* is also transiently expressed during the early stages of T and B cell differentiation but is silenced permanently after T and B cell lineage commitment ([@R1]). Two recent studies support an important regulatory role for *Erg* during murine hematopoiesis ([@R32]; [@R53]). In these studies, mice were characterized containing a single point mutation (Mld2) in the DNA-binding domain of *Erg* that significantly inhibits Erg transactivation. This mutation is associated with multiple defects in definitive hematopoiesis and a failure to sustain self-renewal of hematopoietic stem cells (HSCs), ultimately leading to exhaustion of HSCs and death at E11.5. Interestingly, no defects in cardiac development or vasculogenesis were observed.

Formation of the murine cardiovascular system begins prior to heart tube formation at E7 and involves a series of precisely orchestrated events involving morphogenesis and differentiation. In the heart, the atrioventricular canal (AVC) and outflow tract (OFT) that eventually give rise to the atrioventricular valves and pulmonic and aortic valves, respectively, are characterized by localized swellings called cardiac cushions that are evident by E9.5 ([@R7]). These cushions provide a valve-like function, allowing unidirectional blood flow. The cardiac cushion is composed of myocardial-derived extracellular matrix, which is primarily populated by mesenchymal cells as a result of endocardial-mesenchymal transformation (EnMT) of the endocardial cells in the AVC and OFT ([@R15]). Maturation of the valve is a multistep process involving activation, proliferation, EnMT of the endocardial ECs and, finally, maturation of the cellularized cushions into functional valve leaflets by E13.5. Remodeling of the valve leaflets continues into the postnatal period ([@R41]). This transition is accompanied by upregulation of the Snail family of zinc-finger transcription factors, which are subsequently responsible for the downregulation of EC-specific genes such as *VE-cad* ([@R55]) that lead to the induction of EnMT. Many cell types in the developing embryo that undergo EnMT have been reported to express Ets genes ([@R44]). However, no report to date has suggested a role for any Ets family genes in EnMT during valve morphogenesis.

The primary purpose of this study was to evaluate the role of different Erg isoforms during embryonic development. We identified four Erg isoforms that are highly expressed in articular chondrocytes and share a commonly spliced exon 3, and three Erg isoforms that share a commonly spliced exon 4 and are highly enriched in ECs. Exons 3 and 4 encode separate translational start sites. We report that mice with targeted disruption of exon 3 (*Erg*^ΔEx3/ΔEx3^) are viable, fertile and do not display any overt phenotype. By contrast, targeted disruption of exon 4 (*Erg*^ΔEx4/ΔEx4^) is embryonic lethal and is associated with defects in cardiac and vascular development. The cardiac defects are primarily related to a failure of the endocardial ECs to undergo EnMT. We have identified Erg as a crucial regulator of the zinc-finger transcriptional repressors *Snail1* and *Snail2*, which are required to repress *VE-cad* during EnMT.

MATERIALS AND METHODS {#S2}
=====================

Generation of *Erg*^ΔEx3^ and *Erg*^ΔEx4^ knockout mice and genotyping {#S3}
----------------------------------------------------------------------

To generate the *Erg*^ΔEx3^ knockout construct, 2.4 kb of the 5′ and 3′ flanking regions of exon 3 were amplified by PCR (for primers see [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.081596/-/DC1) Table S1) and cloned on either side of the *lacZ-Neo* cassette and were then inserted into the pM253 vector (kindly provided by Dr W. C. Aird, Boston, MA, USA). The linearized construct was targeted into the *Erg* locus of W4/129S6 ES cells. The targeted ES clones were digested with *Nhe*I and screened by Southern blotting for homologous recombination events (primers used to prepare probes are listed in [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.081596/-/DC1) Table S1). Similarly, 3.8 kb 5′ and 2.5 kb 3′ arms of homology spanning exon 4 of the mouse *Erg* locus were PCR amplified from genomic DNA isolated from the W4/129S6 ES cell line. The fragments were cloned on either side of the *lacZ-Neo* cassette and were inserted into the pM253 vector backbone digested with *Kpn*I and *Xho*I. The plasmid was linearized with *Kpn*I before gene targeting. Two hundred micrograms of linearized and purified plasmid was transfected into W4/129S6 ES cells at 3 μF, 800V ([@R56]). G418 selection at 350 μg/ml was initiated 24 hours following targeting. Neomycin-resistant colonies were screened for homologous recombination by Southern blotting according to standard procedures using 5′ and 3′ probes spanning regions outside the arms of homology that identified *Bss*SI and *Nhe*I restricted fragments, respectively ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.081596/-/DC1) Table S1). Chimeras obtained from blastocyst injections of these positive clones were backcrossed with C57BL/6 mice to obtain mice heterozygous for the inactivated loci. The heterozygotes were inbred to obtain homozygous embryos. Genotyping of embryos and mice was performed by PCR using primers ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.081596/-/DC1) Table S1) that amplified either the wild-type region spanning either exon 3 or exon 4 and/or the *lacZ* cassette. The Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center, Boston, approved all animal experiments (protocol \#101-2010).

β-galactosidase and immunofluorescent staining {#S4}
----------------------------------------------

Mouse conceptuses at different gestational ages (noon of the day in which a vaginal plug was detected was defined as E0.5) were dissected from the extra-embryonic tissues. E7.5-9.5 embryos were fixed in 1% formaldehyde/0.2% glutaraldehyde in PBS for 15 minutes or for 30 minutes for embryos at E10.5-11.5. Embryos were rinsed in PBS for 15-30 minutes at room temperature. The embryos were then processed for β-galactosidase staining as described (<ftp://ftp.sanger.ac.uk/pub4/resources/mouse/sigtr/XGalStaining.pdf>). For routine histology and light microscopy, β-galactosidase-stained embryos were fixed overnight in 4% paraformaldehyde (PFA), embedded in paraffin, sectioned (5 μm) and counterstained with Eosin and photographed. For immunofluorescent staining, embryos were fixed overnight in 4% PFA, rinsed, cryoprotected overnight in 20% sucrose, embedded in OCT (Tissue-Tek) and sectioned (6 μm). Sections were permeabilized with 0.5% Triton X-100 for 5 minutes and blocked in 5% goat serum for 30 minutes. The sections were then incubated with the primary antibody for 1 hour followed by secondary antibody for 45 minutes. Nuclei were stained with 5 ng/ml DAPI, the sections were mounted using Vectastain (Vector Labs) antifade mounting medium and photographed using a Zeiss AxioVision microscope. Antibodies are listed in [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.081596/-/DC1) Table S1.

Quantitative real-time PCR (qRT-PCR) {#S5}
------------------------------------

RNA isolation and cDNA synthesis were performed using the RNeasy Mini kit (Qiagen) and High Capacity RNA-to-cDNA Master Mix (Applied Biosystems) respectively, according to manufacturers\' instructions. qRT-PCR was performed using the StepOnePlus real-time PCR system (Applied Biosystems). All PCR reactions were performed in triplicate. Relative expression was calculated using *Gapdh* as an endogenous internal control. Primers are listed in [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.081596/-/DC1) Table S1.

Ex vivo AVC and OFT explant culture assay {#S6}
-----------------------------------------

Ex vivo explant assays for EnMT were performed as described previously ([@R10]). Briefly, 1.5% rat tail collagen type I (BD Biosciences) was prepared by diluting 3% collagen in cell culture grade water. Equal parts of 2.2% sodium bicarbonate solution and 10× DMEM medium were mixed and added to the collagen solution at 33.3%. The resulting solution was mixed immediately and dispensed into 4-well plates (Nunc) and allowed to solidify for 1 hour inside a 37°C, 5% CO~2~ incubator. The collagen pads were then conditioned for 4 hours with 1× DMEM medium containing 10% fetal bovine serum (FBS). AVC and OFT tissues were dissected from E10.5 embryos and placed on drained collagen pads with the endocardium facing down on the collagen. The explants were allowed to attach for 24 hours at 37°C and 5% CO~2~ in a humidified incubator. Then 1× DMEM with 10% FBS was added to the collagen pads and incubated for an additional 24 hours. Transforming endocardial cells were identified as spindle-shaped cells that either migrated away from the explants or invaded the gel. The collagen pads and explants were fixed overnight with 4% PFA, rinsed several times with PBS and then stained for smooth muscle α-actin (Sigma) and counterstained with anti-mouse Alexa 488 secondary antibody (Invitrogen).

Chromatin immunoprecipitation (ChIP) assays {#S7}
-------------------------------------------

ChIP was performed as described ([@R12]). Briefly, \~50 hearts were isolated from E10.5 *Erg*^+/+^ and *Erg*^ΔEx4/ΔEx4^ mouse embryos, cross-linked for 15 minutes with 1% formaldehyde and lysed. Chromatin was sheared to obtain DNA fragments of 200-500 bp. The chromatin slurry was incubated with anti-mouse Erg (SC354, Santa Cruz). Anti-rabbit IgG was used as a control. The immunoprecipitated DNA fragments were recovered and subjected to qPCR (for primers see [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.081596/-/DC1) Table S1).

RESULTS {#S8}
=======

Genomic structure of *Erg* {#S9}
--------------------------

The mouse *Erg* gene contains 13 exons that span a region of \~225 kb on chromosome 16qC4 ([Fig. 1A](#F1){ref-type="fig"}). By carefully analyzing the UCSC and Ensembl genome databases, we identified seven known transcript variants of mouse *Erg*. Isoforms 1-4 contain the same translational start site within exon 3. Isoforms 1 and 2 differ only in the 5′ UTR. By contrast, isoforms 3 and 4 have a truncated variable region, lacking either exon 9 or 10, respectively. Isoforms 5-7 have a separate translational start site within exon 4. Isoforms 5-7 differ by the presence or absence of exons 9 and 10 in the variable region. All isoforms contain the Ets DNA-binding domain and the pointed domain (PNT) known to be crucial for protein-protein interactions ([Fig. 1A](#F1){ref-type="fig"}).

![**Genomic structure and expression of mouse *Erg* isoforms.** (**A**) Genomic organization of *Erg* and representation of the different isoforms that result from the presence of two independent translation start sites within exons 3 and 4. The seven isoforms differ in the variable region and in the 5′ UTR. F1 and R1 denote forward and reverse qPCR primers used to identify *Erg* isoforms 1-4, whereas primers F2 and R2 were used to identify *Erg* isoforms 5-7. The pointed (PNT), variable and Ets domains are indicated. (**B-E**) Real-time PCR analysis of differential *Erg* isoform expression in various mouse cell lines. Isoforms 1-4 are predominantly expressed in non-endothelial cells (ECs) and in articular cartilage (B), whereas isoforms 5-7 are predominantly expressed in ECs (C). Similarly, adult organs enriched in blood vessels, such as heart and lung, predominantly express isoforms 5-7 (E), whereas organs such as the trachea with large amounts of chondrocytes express isoforms 1-4 (D). Error bars indicate s.d. of at least three independent qPCR reactions.](DEV081596F1){#F1}

Differential expression of Erg isoforms in chondrocytes and ECs {#S10}
---------------------------------------------------------------

Previous studies have demonstrated differential expression of Erg in chondrocytes of developing bone and in ECs during vascular development ([@R27]; [@R40]; [@R64]). Isoform-specific primers were designed to evaluate the expression of *Erg* in different cell types in mouse tissues and cultured cells ([Fig. 1B-E](#F1){ref-type="fig"}). Isoforms 1-4 exhibit high levels of expression in articular chondrocytes such as AtdcD13 and minimal expression in all other cell types tested. By contrast, isoforms 5-7 are highly expressed in mouse ECs including MS1, bEND and PY41, but not in other cell types, and in organs with abundant ECs such as the lung and heart.

Generation of *Erg* exon 3 and exon 4 knockout mice {#S11}
---------------------------------------------------

To further define the role of exon 3- and exon 4-specific isoforms during development, we generated *Erg*^ΔEx3/ΔEx3^ and *Erg*^ΔEx4/ΔEx4^ knockout mice using standard gene targeting strategies. In brief, we designed a targeting vector to replace either the ATG of exon 3 or exon 4 with a *lacZ-Neo* cassette ([Fig. 2A,C](#F2){ref-type="fig"}). Targeting of these exons blocks protein expression of Erg isoforms 1-4 and 5-7, respectively, which is replaced by expression of *lacZ*. Mouse ES cells were transfected with the linearized targeting vectors and neomycin-resistant ES cell clones were picked and screened. Successful homologous recombination was verified by PCR and Southern blot analysis ([Fig. 2B,D](#F2){ref-type="fig"}). *Erg*^ΔEx3/+^ and *Erg*^ΔEx4/+^ ES cells were used to produce *Erg*^ΔEx3/+^ and *Erg*^ΔEx4/+^ heterozygous knockout mice, respectively. *lacZ* staining was first observed in the *Erg*^ΔEx3/+^ mice at E9.5 and in *Erg*^ΔEx4/+^ mice at E7.5 ([Fig. 3A](#F3){ref-type="fig"}).

![**Targeting of *Erg***^Δ^**^Ex3/+^ and *Erg***^Δ^**^Ex4/+^ loci.** (**A**) The wild-type murine *Erg* locus, the targeting construct, and targeted locus with exon 3 replaced by the *lacZ-Neo* reporter cassette. The numbered boxes represent *Erg* exons. Bold lines indicate the arms of homology. The positions of Southern blotting probes are indicated. (**B**) Southern analysis to identify *Erg*^ΔEx3/+^ ES cell clones using 5′ and 3′ probes that distinguish *Nhe*I fragments in the wild-type and targeted alleles. (**C**) *Erg* wild-type locus, the targeting construct, and targeted locus with exon 4 replaced by the *lacZ-Neo* reporter cassette. (**D**) Southern analysis to identify *Erg*^ΔEx4/+^ ES cell clones using 5′ and 3′ probes that distinguish *Bss*SI and *Nhe*I fragments in the wild-type and targeted allele, respectively.](DEV081596F2){#F2}

![***lacZ* expression pattern during development of *Erg***^Δ^**^Ex3/+^ and *Erg***^Δ^**^Ex4/+^ mouse embryos.** (**A**) *lacZ* staining corresponding to *Erg*^Ex3^ was observed in the somites and limbs corresponding to developing articular cartilage starting at E9.5. By contrast, *Erg*^Ex4^ expression was detected in the blood islands at E7.5 and then in all embryonic vasculature. (**B**,**D**,**F**) *lacZ* staining of whole-mount preparations of the head (B), heart (D) and somites (F) from E10.5 embryos displaying a clear endothelial restricted pattern in the brain vasculature, endocardium and intersomitic vessels, respectively. (**C**,**E**,**G**) *lacZ* staining of sectioned E10.5 embryos. *lacZ*-positive cells are seen in the vitelline artery (C), endocardium of the heart (E) and in ECs lining the dorsal aorta (G).](DEV081596F3){#F3}

*Erg*^ΔEx3/ΔEx3^ mice do not display any overt phenotype {#S12}
--------------------------------------------------------

*lacZ* staining in *Erg*^ΔEx3/+^ and *Erg*^ΔEx3/ΔEx3^ was first observed at E9.5 in the limb bud. At E10.5, expression was seen in the spine and ear regions. By E12.5, *lacZ* expression was detected in all bony joints, including the skull, spine and limbs ([Fig. 3A](#F3){ref-type="fig"}). To further define the cellular distribution of the *lacZ* staining in the joints, 10 μm sections of the knee joints from postnatal day (P) 4 pups were counterstained with eosin ([Fig. 4](#F4){ref-type="fig"}). We observed strong *lacZ* staining only in the articular cartilage in the *Erg*^ΔEx3/+^ and *Erg*^ΔEx3/ΔEx3^ P4 mice. This is consistent with the *Erg* expression pattern previously observed in the mouse by in situ hybridization ([@R28]). No appreciable morphological changes were observed in the joints of *Erg*^ΔEx3/ΔEx3^ versus control P7 mice. Radiographs of *Erg*^+/+^ and *Erg*^ΔEx3/ΔEx3^ mice revealed no differences in joint bone structure at 4 or up to 14 months of age (data not shown). Despite the wide expression pattern of Erg isoforms 1-4 in the developing cartilage and joints, the homozygous null animals were viable, fertile and did not display any overt phenotype.

![***Erg*^Ex3^ is expressed in the developing joints.** (**A-H**) Whole-mount *lacZ* staining of *Erg*^+/+^ (A,E) and *Erg*^ΔEx3/ΔEx3^ (B-D,F-H) mouse embryos at E10.5 and E12.5 showing expression in the developing limb (C,G) and skull (D,H). (**I-P**) *lacZ* staining of *Erg*^+/+^ (I,M) and *Erg*^ΔEx3/ΔEx3^ (J-L,N-P) mice at E18.5 and P4.](DEV081596F4){#F4}

*Erg*^ΔEx4/ΔEx4^ mice are embryonic lethal at E10.5-11.5 {#S13}
--------------------------------------------------------

*lacZ* expression in *Erg*^ΔEx4/+^ was seen throughout the entire vasculature of the embryo proper by E8.5-10.5 (3A-G) with particular accentuation of expression in the endocardium of the AVC. This pattern of *lacZ* expression was similar to the endothelial expression pattern that we reported previously by Erg immunohistochemistry in the developing mouse embryo ([@R40]). The homozygous *Erg*^ΔEx4/ΔEx4^ embryos appeared smaller than heterozygous or *Erg*^+/+^ embryos by E9.5 ([Fig. 5A,B](#F5){ref-type="fig"}). By E10.5, the embryos also displayed a significant reduction in size and exhibited hemorrhages in the head, trunk, or both regions ([Fig. 5D](#F5){ref-type="fig"}; see [Fig. 7A-D](#F7){ref-type="fig"}). These abnormalities were more striking in surviving embryos at E11.5, with marked reductions in the size and vascularization of *Erg*^ΔEx4/ΔEx4^ embryos ([Fig. 5F](#F5){ref-type="fig"}). No live *Erg*^ΔEx4/ΔEx4^ embryos were observed beyond E11.5 ([Table 1](#T1){ref-type="table"}).

![**Morphology of *Erg***^Δ^**^Ex4/+^ and *Erg***^Δ^**^Ex4/^**^Δ^**^Ex4^ embryos.** (**A**,**B**) At E9.5, *lacZ* expression in *Erg*^ΔEx4/+^ is seen in all embryonic vasculature. The *Erg*^ΔEx4/ΔEx4^ embryos were smaller (B), but did not display any other significant morphological differences when compared with controls (A). (**C**,**D**) By E10.5, *Erg*^ΔEx4/ΔEx4^ embryos (D) were notably smaller than control littermates (C), were paler and displayed disrupted vessels associated with hematoma (arrows). (**E**,**F**) Surviving *Erg*^ΔEx4/ΔEx4^ embryos at E11.5 (F) showed a dramatic reduction in size and development compared with controls (E).](DEV081596F5){#F5}

###### 

Genotype analysis of progeny from *Erg*^ΔEx4^ heterozygous intercrosses

![](3973tbl1)

*Erg*^ΔEx4/ΔEx4^ embryos exhibit abnormal vascular remodeling {#S14}
-------------------------------------------------------------

Vascular defects in the *Erg*^ΔEx4/ΔEx4^ embryos were observed as early as E10.5. The large arborized vessels that are characteristic of the remodeled vascular plexus were completely absent in the yolk sac of *Erg*^ΔEx4/ΔEx4^ embryos ([Fig. 6B](#F6){ref-type="fig"}). Whole-mount CD31 (Pecam1) staining of the *Erg*^ΔEx4/ΔEx4^ yolk sac revealed that the primary capillary plexuses were present but that these capillaries failed to fuse into the larger vessels seen in the controls ([Fig. 6B](#F6){ref-type="fig"}), indicating a vascular remodeling defect.

![**Vascular remodeling defects seen in *Erg***^Δ^**^Ex4/^**^Δ^**^Ex4^ embryos at E10.5.** (**A**,**B**) CD31 staining shows that mutant yolk sac (B) lacks larger vessels, displaying only a capillary plexus when compared with controls that display a well-organized vasculature (A). (**C**,**D**) *Erg*^ΔEx4/ΔEx4^ embryos show vascular remodeling abnormalities in the head (D), failing to exhibit normal alignment and invasion of vessels from the perineural vascular plexus into the developing ganglionic eminence, as seen in controls (C) (arrowheads). Insets are low-magnification images of the head. (**E**,**F**) CD31 staining of vasculature in the placental labyrinth at E10.5 shows abundant vessels in *Erg*^ΔEx4/+^ (E), whereas the *Erg*^ΔEx4/ΔEx4^ embryos display collapsed and pooled vessels (F).](DEV081596F6){#F6}

Vascularization of the central nervous system begins at \~E10.0, when angiogenic vessels from the perineural vascular plexus invade the embryonic neuroectoderm ([@R35]; [@R45]). In E10.5 *Erg*^ΔEx4/ΔEx4^ embryo brains we failed to detect a normal alignment and invasion of vessels from the perineural vascular plexus into the developing ganglionic eminence, as seen in the controls ([Fig. 6C,D](#F6){ref-type="fig"}, arrowheads). We consistently observed disrupted vessels by CD31 staining ([Fig. 7E-J](#F7){ref-type="fig"}) and hemorrhages ([Fig. 7A-D](#F7){ref-type="fig"}) in the brain of *Erg*^ΔEx4/ΔEx4^ embryos.

![***Erg***^Δ^**^Ex4/^**^Δ^**^Ex4^ embryos display hemorrhages and disrupted vasculature.** (**A-D**) Whole-mount images of *Erg*^+/+^ and *Erg*^ΔEx4/ΔEx4^ mouse embryos at E10.5. *Erg*^ΔEx4/ΔEx4^ embryos are growth retarded (B-D) and show hemorrhages (arrows in B-D) when compared with controls (A). (**E**,**F**) CD31 whole-mount immunohistochemistry of head of *Erg*^+/+^ (E) and *Erg*^ΔEx4/ΔEx4^ (F) embryos at E10.5. (**G-J**) Magnified images of the boxed regions in E and F. Note the well-connected minor branches in the controls (G), whereas the mutants display a disorganized pattern of vasculature (H). (**I**) Wild-type embryo showing a segmented pattern of intersomitic vessels and capillary network, as compared with the severe disorganization of intersomitic vessels and reduced capillary network in *Erg*^ΔEx4/ΔEx4^ embryos (J). (**K**,**L**) E10.5 *Erg*^ΔEx4/ΔEx4^ embryo revealing pericardial effusion (K); the boxed region is magnified in L (arrow points to the effusion).](DEV081596F7){#F7}

We also observed defective vasculature in the labyrinth region of the placenta in *Erg*^ΔEx4/ΔEx4^ embryos. Whereas the controls displayed normal placental villi and capillaries, in the *Erg*^ΔEx4/ΔEx4^ placentas the capillaries were not clearly discernible by CD31 staining ([Fig. 7F](#F7){ref-type="fig"}). Instead, the placental capillaries appeared collapsed, with a drastic reduction in fetal blood ([Fig. 8F](#F8){ref-type="fig"}, arrows), possibly a consequence of abnormal cardiac function and circulatory collapse. Taken together, these results indicate that the vasculature in both the embryo and extra-embryonic tissues of *Erg*^ΔEx4/ΔEx4^ has vascular remodeling defects.

![**Placental vascular defects in *Erg***^Δ^**^Ex4/^**^Δ^**^Ex4^ embryos at E10.** (**A**,**B**) The dashed lines in *Erg*^+/+^ (A) and *Erg*^ΔEx4/ΔEx4^ (B) indicate the extent of decidual invasion in each placental section. (**C**,**D**) Magnification of the boxed areas in A and B. Well-defined vasculature is observed in *Erg*^+/+^ placentas (C), whereas the mutants, although they have abundant maternal blood sinuses, lack well-defined fetal-derived capillaries (D). (**E**,**F**) Higher magnification of C and D reveal abundant nucleated fetal blood in the controls (arrows, E), whereas the mutants show a drastic reduction in the number of fetal blood cells and exhibit collapsed capillaries (arrows, F). D, maternal decidua; L, labyrinth; E, embryo; MB, maternal blood; EB, embryonic blood.](DEV081596F8){#F8}

Endocardial Erg is necessary for endocardial cushion development {#S15}
----------------------------------------------------------------

At E10.5, many *Erg*^ΔEx4/ΔEx4^ embryos exhibited pericardial effusions ([Fig. 7K,L](#F7){ref-type="fig"}), a classic sign of cardiac dysfunction. β-galactosidase-stained sections of control and *Erg*^ΔEx4/ΔEx4^ embryos that had reached similar developmental stage revealed trabeculae that were well connected to the myocardium of the ventricular wall, and the β-galactosidase-stained ECs lined the trabeculae in both the *Erg*^+/+^ and *Erg*^ΔEx4/ΔEx4^ heart ([Fig. 9A,B](#F9){ref-type="fig"}). We observed regional swellings of the extracellular matrix in the AVC and OFT ([Fig. 9C-F](#F9){ref-type="fig"}) of the heart in both control and mutant embryos; however, invasion of the mesenchyme was dramatically decreased in the mutants ([Fig. 9D,F](#F9){ref-type="fig"}). The endocardial cells maintained their adherens junctions and failed to invade the cardiac extracellular matrix, as observed by VE-cad staining of the AVC and OFT ([Fig. 10A,B](#F10){ref-type="fig"}). By contrast, VE-cad in other tissues, such as the developing lung ([Fig. 10C-F](#F10){ref-type="fig"}), showed a significant reduction in the knockouts compared with wild-type controls.

![**Drastic reduction in EnMT in *Erg*^ΔEx4/ΔEx4^ during valve morphogenesis.** (**A-F**) Hearts of *Erg*^ΔEx4/+^ (A,C,E) and *Erg*^ΔEx4/ΔEx4^ (B,D,F) mouse embryos at E10.5 stained for β-galactosidase and sagittally sectioned. The AVC and OFT mesenchymal cells that form normally in control embryonic hearts (C,E) are drastically reduced in the mutant (D,F). AVC, atrioventricular canal; OFT, outflow tract; A, atrium; V, ventricle.](DEV081596F9){#F9}

![**Endocardial cells maintain their adherens junctions in *Erg***^Δ^**^Ex4/^**^Δ^**^Ex4^ embryos.** (**A**,**B**) Heart sections from E10.5 *Erg*^+/+^ and *Erg*^ΔEx4/ΔEx4^ mouse embryos stained for VE-cadherin reveal that the endocardial cells maintain their adherens junctions and fail to invade the cardiac jelly in the mutants. Arrowheads, VE-cadherin staining. (**C-F**) Lung bud sections of E10.5 *Erg*^+/+^ and *Erg*^ΔEx4/ΔEx4^ embryos reveal a reduction in VE-cadherin staining in the mutant. A, atrium; AVC, atrioventricular canal.](DEV081596F10){#F10}

We next analyzed the transformation of endocardial cells to mesenchymal cells by performing AVC and OFT explant cultures, using a collagen gel culture system ([@R46]), from E9.5 and E10.5 embryos, respectively. Endocardial cells from *Erg*^+/+^ AVC and OFT explants were motile and invaded the collagen matrix, whereas the cells from *Erg*^ΔEx4/ΔEx4^ explants showed a marked reduction in migration and invasion ([Fig. 11A](#F11){ref-type="fig"}). We further characterized EnMT in the *Erg*^ΔEx4/ΔEx4^ and *Erg*^+/+^ AVC and OFT explant cultures by immunofluorescence analysis. The explants were stained for the mesenchymal marker smooth muscle α-actin (α-SMA) and stained cells that had migrated away from the explant into the matrix were counted and quantified ([Fig. 11B,C](#F11){ref-type="fig"}). α-SMA-stained cells were found in abundance in *Erg*^+/+^ explants, whereas very few were observed in the explants from *Erg*^ΔEx4/ΔEx4^ embryos ([Fig. 11C](#F11){ref-type="fig"}).

![**Deletion of endothelial enriched Erg in endocardial cells prevents EnMT in vitro.** (**A**) In vitro collagen gel assays performed with AVC and OFT explants isolated from *Erg*^+/+^ (**i**,**iii**) or *Erg*^ΔEx4/ΔEx4^ (**ii**,**iv**) E10.5 hearts. The number of invading and migrating cells formed in *Erg*^+/+^ explants was substantially higher than in *Erg*^ΔEx4/ΔEx4^ explants. (**B**) *Erg*^+/+^ (**i**,**iii**) and *Erg*^ΔEx4/ΔEx4^ (**ii**,**iv**) explant cultures stained with an antibody (green) against the mesenchymal marker α-SMA. Nuclei were visualized by staining with DAPI (blue). (**C**) The numbers of mesenchymal cells formed in *Erg*^+/+^ (*n*=12) and *Erg*^ΔEx4/ΔEx4^ (*n*=7) explants were quantified. The number of migrating and invading mesenchymal cells was 16.66±2% in the AVC and 13.15±2% in the OFT regions in *Erg*^ΔEx4/ΔEx4^ compared with the *Erg*^+/+^ embryos. \**P*\<0.005. Error bars indicate s.d.](DEV081596F11){#F11}

Genes involved in EnMT are differentially regulated in *Erg*^ΔEx4/ΔEx4^ hearts {#S16}
------------------------------------------------------------------------------

In an attempt to identify regulators and downstream targets of Erg in endocardial cushion formation, we collected RNA from *Erg*^+/+^ and *Erg*^ΔEx4/ΔEx4^ hearts at E10.5 and isolated RNA for qRT-PCR analysis of several genes involved in EnMT in the developing heart ([Fig. 12A](#F12){ref-type="fig"}; [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.081596/-/DC1) Table S1). Of the genes analyzed, *Snail1* (also known as *Snail* or *Snai1*) and *Snail2* (*Slug* or *Snai2*) were significantly downregulated in *Erg*^ΔEx4/ΔEx4^ heart. *Snail1* and *Snail2* encode zinc-finger transcriptional repressors that have been reported to induce EnMT during embryonic development. Deficiency of *Snail2* is partially rescued by the expression of *Snail1* ([@R39]). Accordingly, deficiency of both *Snail1* and *Snail2* leads to lethality at E10.5 from EnMT defects ([@R38]). This helped us identify *Snail1* and *Snail2* as potential downstream targets of Erg. *Snail2* has been reported to be a direct target of Notch during EnMT and cardiac cushion cellularization ([@R55]; [@R21]; [@R39]). Interestingly, there were no significant changes in the expression of *Notch1/4, Bmp2/4* or *Tgfb1/2*, which are the main pathways involved during valve morphogenesis. Consistently, hearts stained with Snail1 plus Snail2 antibody revealed a drastic reduction in the number of stained cells in the AVC region ([Fig. 12C](#F12){ref-type="fig"}) and OFT (data not shown) of *Erg*^ΔEx4/ΔEx4^ embryos compared with *Erg*^+/+^ controls ([Fig. 12B](#F12){ref-type="fig"}). These data suggest that Erg acts downstream of crucial regulators such as Notch, BMP and Tgfβ and upstream of *Snail1* and *Snail2*.

![***Erg***^Δ^**^Ex4/^**^Δ^**^Ex4^ embryos show changes in genes regulating EnMT.** (**A**) Differential expression of genes that regulate EnMT in *Erg*^ΔEx4/ΔEx4^ compared with *Erg*^+/+^ E10.5 heart samples. For each gene evaluated, control expression was normalized to 1 in order to compare the relative change in expression in the knockout versus control. Error bars indicate s.d. of at least six independent qPCR reactions per genotype. (**B**,**C**) Snail1 plus Snail2 staining of sections of *Erg*^+/+^ and *Erg*^ΔEx4/ΔEx4^ AVC regions at E10.5, showing a marked reduction in Snail1/2-positive cells in the mutant. Dashed lines outline the endocardial cells. (**D**,**E**) Representative serial sections of B and C, respectively, stained with IgG controls. A, atrium; AVC, atrioventricular canal.](DEV081596F12){#F12}

Erg binds to highly conserved Ets binding sites in the *Snail1* proximal promoter and *Snail2* intronic region {#S17}
--------------------------------------------------------------------------------------------------------------

To examine whether *Snail1* and *Snail2* are direct targets of Erg, we first analyzed the proximal promoter and intronic regions of *Snail1* and *Snail2* for highly conserved Ets binding sites. We identified one highly conserved Ets binding site at −650 in the proximal promoter of *Snail1* ([Fig. 13A](#F13){ref-type="fig"}). Similarly, the intronic region of *Snail2* at +157 contained a highly conserved Ets binding domain ([Fig. 13B](#F13){ref-type="fig"}). To evaluate whether Erg binds to these regions in vivo, we conducted ChIP assays from mouse embryo hearts at E10.5 using an Erg antibody. Hearts from *Erg*^ΔEx4/ΔEx4^ embryos were employed as negative controls. From the genomic DNA fragments immunoprecipitated with Erg antibody, amplification of the regions spanning the Ets binding sites were analyzed by qPCR ([Fig. 13C,D](#F13){ref-type="fig"}; [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.081596/-/DC1) Table S1). A significant amplification of the region spanning the Ets binding sites was observed in the *Erg*^+/+^ heart samples compared with the IgG or negative controls. It is imperative to note that the input was diluted 1:200 because whole embryo hearts were used for the assay and it is likely that Erg may only regulate *Snail1* and *Snail2* in a subset of cells, and therefore the signal might not be highly enriched over the input. Overall, these results indicate that Erg binds specifically to regulatory regions in the *Snail1* and *Snail2* genes in E10.5 heart.

![**Conserved Ets binding sites in the *Snail1* promoter and *Snail2* intronic regions.** (**A**) The mouse *Snail1* promoter region showing conserved Ets binding sites (EBS, vertical bars). The *Snail1* promoter sequences from mouse, rat, human, orangutan and dog are aligned. Highly conserved Ets DNA binding sites were identified within the red box at −650 as analyzed using the UCSC genome browser. (**B**) The mouse *Snail2* promoter region showing conserved Ets binding sites. The *Snail2* promoter sequences from mouse, rat, human, orangutan, dog and horse are aligned. Highly conserved Ets DNA binding sites were identified within the red box at +157 using the UCSC genome browser. (**C**) ChIP analysis of Erg binding at the *Snail1* −650 site by qPCR. (**D**) Quantitative ChIP analysis of Erg binding at the *Snail2* +157 site using real-time PCR. (C,D) The input DNA control sample (1:200) was used to normalize the quantification of each PCR product. Rabbit IgG and hearts from *Erg*^ΔEx4/ΔEx4^ embryos were employed as negative controls.](DEV081596F13){#F13}

DISCUSSION {#S18}
==========

Ets transcription factors regulate the expression of several genes that are important for signaling pathways involved in cell differentiation during embryonic development. They influence cell specification and coordinate changes in the expression of adhesion molecules and the degradation of the extracellular matrix, thereby regulating cell motility, epithelial-mesenchymal transition (EMT) interactions, morphogenesis during embryonic development, as well as other physiological and pathological processes ([@R36]; [@R43]; [@R59]; [@R33]; [@R60]). During embryonic development, EMT is crucial for appropriate differentiation and is a mechanism for dispersing cells ([@R30]). The EMT program allows cells to separate from neighboring cells, become motile and migrate to other locations ([@R5]). For example, in the developing embryo the neural crest develops from a small portion of the dorsal neural tube ([@R47]; [@R37]). The neural crest cells then undergo EMT, migrate and differentiate into bone, smooth muscle cells, peripheral neurons, glia and melanocytes. Similarly, in the heart, the endocardial ECs lining the AVC undergo EMT to form the earliest progenitors of the tricuspid and mitral valves. Likewise, the ECs in the OFT undergo EMT to form the precursors of the aortic and pulmonary valves ([@R17]).

Among the Ets factors known to regulate EMT, Ets1 expression in the chick embryo is induced in cranial neural folds and in migrating neural crest cells ([@R52]). Although Ets1 does not directly induce EMT, it cooperates with Snail2 to initiate EMT ([@R54]). In murine embryos, Ets1 is expressed in mesenchymal cells adjacent to epithelial structures where EMT is initiated and matrix metalloproteases (MMPs) are activated ([@R31]). *Ets2* knockout mice die in utero at E8.5 with defects associated with misexpression of MMP9, leading to a failure in extracellular matrix remodeling, indicating a role of *Ets2* in EMT ([@R62]). In humans, ETS1 plays a role in tumor invasion and vascularization by regulating the expression of MMPs in ECs, thereby activating EMT ([@R19]). Similarly, the PEA3 subfamily of the Ets family directly targets MMPs in tumor settings, thereby promoting EMT ([@R58]; [@R25]). By contrast, the prostate-derived Ets factor (PDEF) suppresses EMT by negatively regulating the expression of Snail2 ([@R20]). Along similar lines, Erg is also involved in epithelial-mesenchymal interactions through the regulation of extracellular matrix proteins, including stromelysin 1 and collagenase 1 ([@R8]).

Despite evidence supporting a role for Ets factors in EMT, any involvement in regulating valve morphogenesis in the developing heart has not been previously reported. Transcripts for several Ets factors, including *Erg* and *Ets1*, have been recently identified in the E8.5 mouse heart ([@R49]). Furthermore, Ets1 and Erg were shown to directly regulate *Gata4* in the mouse embryonic heart by binding to a distal enhancer region within the *Gata4* gene. In the current study, we have identified an important regulatory role for the EC-enriched Ets factor Erg in the regulation of murine vascular development. Our data indicate that *Erg* is expressed throughout the entire vasculature during early development from E7.5. Previous studies, including those from our own laboratory, have shown an important role for Erg in the regulation of a number of EC-enriched genes, including *VE-cad*, claudin 5, *Vwf*, endoglin and angiopoietin 2 ([@R6]; [@R65]; [@R50]; [@R42]; [@R23]). In the current study we report a novel and essential role for Erg during valve morphogenesis in the developing mouse heart. Deletion of the EC-enriched isoforms leads to lethality between E10.5 and E11.5, with reduced EnMT during valve morphogenesis. We show for the first time the involvement of an Ets factor in fate determination of endocardial cells during the initiation of cardiac cushion cellularization. We further demonstrate that Erg binds directly to the proximal promoter of *Snail1* at the −650 bp region and to the intronic region of *Snail2* at +157, thereby regulating the expression of the core regulatory transcription factors controlling EnMT. Similar to *Erg*, murine *Gata4* encodes several isoforms that are expressed in multiple tissues. An endocardial-specific distal *Gata4* enhancer could regulate the expression of selected Gata4 isoforms within the endocardium of the developing heart. Future studies will be needed to further define the important regulatory elements within the *Erg* gene that direct selected isoforms not only to the endothelium but also, perhaps more selectively, to the endocardium.

Endocardial cushion formation and EnMT are regulated by a number of pathways, either synergistically or via inhibitory interactions ([@R15]). Studies in chicken first suggested that Tgfβ2 and Tgfβ3 are the major myocardial EnMT inducers. Given that mice deficient for either of these factors do not exhibit dramatic EnMT defects in vivo ([@R16]; [@R29]; [@R48]; [@R4]; [@R51]), it was later suggested that other factors, such as Bmp2, that function upstream of *Tgfb2* are crucial inducers of EnMT and cushion formation in the AVC ([@R34]). Within the endocardial cells destined to undergo EnMT, Notch signaling is a crucial regulator of this process. Mice with targeted disruption of *Notch1* die in utero with severe defects in valve morphogenesis as the AVC fails to undergo cellularization ([@R55]). Loss of expression of Notch targets such as *Snail1* and *Snail2* lead to failure of cells to undergo EnMT. Snail1 and Snail2 are transcriptional repressors of *VE-cad*, thereby inducing EnMT by downregulating endocardial cell adhesion. *Notch1* mutants also display reduced *Tgfb2* expression in the AVC and OFT regions ([@R55]), suggesting that Notch signaling exerts a non-cell-autonomous effect in myocardial Tgfβ2 signaling. In our studies, we did not observe a significant change in *Notch1*, placing *Erg* downstream of *Notch1*. The most significant change was observed in the levels of *Snail1* and *Snail2*, both of which are Notch1 targets required to repress the expression of *VE-cad* in the endocardium. These results appear paradoxical given that Erg is known to activate *VE-cad* expression in ECs ([@R6]), and, in support, we too see an overall reduction of *VE-cad* in other tissues, including the lung bud ([Fig. 10C-F](#F10){ref-type="fig"}). However, this phenomenon is not previously unreported for Erg. Higher levels of androgen receptor (AR) activity have been shown to increase Erg protein through TMPRSS2 regulatory regions, which in turn downregulates AR and Erg, and vice versa in prostrate cancers ([@R63]). It is similarly possible that Erg and the Snail1/2 transcription factors function in a negative autoregulatory loop so that Erg and VE-cad are suppressed by Snail1/2 once they are induced by Erg.

Cardiac valve development is also tightly regulated by the differential expression of several transcription factors. During the early stages of heart development, the cardiac chambers are formed when the linear heart tube loops rightward, balloons outward and the endocardial cushions appear at the level of the AVC and OFT. The newly formed endocardial cushions are marked by the expression of selected transcription factors, including the T-box factor *Tbx2* ([@R22]). Interestingly, we observed a marked downregulation of *Tbx2* in our *Erg* mutant hearts. EnMT involves overlapping steps of repopulation, differentiation and migration of ECs into the cardiac jelly ([@R2]). Hence, during the first step, endocardial cells that are fated to transdifferentiate and are destined to undergo EnMT delaminate. During this process, expression of the Snail1/2 transcription factors leads to marked repression of *VE-cad*, allowing the endocardial cells to separate from each other. The *Erg* knockout embryos show substantially decreased levels of Snail1/2 and a sustained expression of VE-cad, indicating a failure of the endocardial cells to undergo transdifferentiation. The T-box factor *Tbx20* has recently been shown to be involved in early AVC development. EnMT is markedly perturbed in mice lacking *Tbx20* ([@R9]). In addition to *Tbx2*, we also observed significant reductions in *Tbx20* in *Erg* knockout mice. Similarly, *Msx1* and *Msx2*, which belong to the Nk family of homeobox genes, have also been shown to play an overlapping regulatory role in BMP-induced cardiac EnMT ([@R13]). We also observed a significant reduction in the expression level of *Msx1* in the Erg-deficient embryonic hearts.

During the second stage of EnMT, the endocardial cells repopulate and replace the cells undergoing transdifferentiation, a process that is controlled by Vegf signaling through Nfatc1 ([@R61]). Our mutant embryos did not show a significant change in *Nfatc1* expression, which is consistent with its recently described role in the inhibition of EnMT during valve development ([@R61]). During the third stage of EnMT, the endocardial cells destined to undergo EnMT are then subjected to hyaluronic acid signaling and signaling through ErbB2/3 heterodimers that promote cell migration into the cardiac jelly ([@R11]). Consistently, the *Erg* knockout embryos showed decreased *Erbb2*. It is also possible that Ets factors can interact cooperatively with other factors to regulate EnMT in the heart. Recent evidence shows that the Ets factor ETV5 regulates the EnMT process in endometrial carcinomas through crosstalk with lipoma-preferred partner protein as a principal event in initiating EC invasion ([@R14]).

In conclusion, the current study identifies a previously unknown function of *Erg* during valve morphogenesis and clearly delineates functional variation in isoform-specific activity. These findings also suggest that isoform-specific *Erg* mutations might underlie some forms of human congenital cardiac valve defects.
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